肝硬化顽固性腹水的治疗新进展*

doi:10.3969/j.issn.1672-5069.2011.04.036

摘要/Abstract

摘要： 腹水是肝硬化失代偿期最常见的并发症，其中20%的肝硬化腹水最终发展为顽固性腹水。顽固性腹水易并发多种致命性疾病，治疗难度大，危险性高。本文详述了2009年美国肝病研究学会有关顽固性腹水的治疗策略及推荐意见。

刘红虹,罗生强,福军亮,王福生. 肝硬化顽固性腹水的治疗新进展^*[J]. 实用肝脏病杂志, 2011, 14(4): 317-320.

[1] ARROYO V，GINES P，GERBES AL，et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis[J]. Hepatology，1996，23:164-176.
[2] BOYER TD，ZIA P，REYNOLDS TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease[J]. Gastroenterology，1979，77:215-222.
[3] PEREZ-AYUSO RM，ARROYO V，PLANAS R，et al. Randomized comparative study of efficacy of furosemide vs. spironolactone in nonazotemic cirrhosis with ascites[J]. Gastroenterology，1983，84:961-968.
[4] STANLEY MM，OCHI S，LEE KK，et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites[J]. N Engl J Med，1989，321:1632-1638.
[5] GINES P，ARROYO V，QUINTERO E，et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites:results of a randomized study[J]. Gastroenterology，1987，93:234-241.
[6] RUNYON BA. Care of patients with ascites[J]. N Engl J Med，1994，330:337-342.
[7] RUNYON BA. Ascites and spontaneous bacterial peritonitis.in:Feldman M，Friedman LS，Brandt LJ，eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 8th ed[J]. Philadelphia，PA: Saunders；2006:1935-1964.
[8] RUNYON BA. Paracentesis of ascitic fuid:a safe procedure[J].Arch Intern Med，1986，146:2259-2261.
[9] GRABAU CM，CRAGO SF，HOFF LK，et al. Performance standards for the therapeutic abdominal paracentesis[J]. Hepatology，2004，40:484-488.
[10] GINES P，TITO L，ARROYO V，et al. Randomize study of therapeutic paracentesis with and without intravenous albumin in cirrhosis[J]. Gastroenterology，1988，94:1493-1502.
[11] GINES A，FERNANDEZ-ESPARRACH G，MONESCILLO A，et al. Randomized trial comparing albumin，dextran70，an polygeline in cirrhotic patients with ascites treated by paracentesis[J]. Gastroenterology，1996，111:1002-1010.
[12] SALO J，GINES A，GINES P，et al. Effect other therapeutic paracentesis on plasma volume and transvascular escape of albumin in patients with cirrhosis[J]. J Hepatol，1997，27:645-653.
[13] ROTHSCHILD M，ORATZ M，EVANS C，et al. Alterations in albumin metabolism after serum and albumin infusions[J]. J Clin Invest，1964，43:1874-1880.
[14] WILKINSON P，SHERLOCK S. The effect of repeated albumin infusions in patients with cirrhosis[J]. Lancet，1962，ii:1125-1129.
[15] PIETRANGELO A，PANDURO A，CHOWDHURY JR，et al. Albumin gene expression is down-regulated by albumin or macromolecule infusion in the rat[J]. J Clin Invest，1992，89:1755-1760.
[16] HAYNES GR，NAVICKIS RJ，WILKES MM. Albumin administration-what is evidence of clinical benefit A systematic review of randomize controlled trials[J]. Eur J Anaesth，2003，20:771-793.
[17] AMERICAN THORACIC SOCIETY. Evidence-based colloid use in the critical ill: American Thoracic Society Consensus Statement[J]. Am J Respir Cri Care Med，2004，170:1247-1259.
[18] CABRERA J，INGLADA L，QUINTERO E，et al. Large-volume paracentesis and intravenous saline:effects on the renin angiotensin system[J]. Hepatology，1991，14:1025-1028.
[19] CHRISTIDIS C，MAK F，RAMOS J，et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions[J]. J Hepatol，2001，35:726-732.
[20] SINGH V，KUMAR R，KANWAL C，et al. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis:a randomized trial[J]. J Gastroenterol Hepatol，2006，21:303-307.
[21] CHOI CH，AHN SH，KIM DY，et al. Long-term clinical outcome of large volume paracentesis with intravenous albuminin patients with spontaneous bacterial peritonitis:a randomize prospective study[J]. J Gastroentero Hepatol，2005，20:1215-1222.
[22] HEUMAN DM，ABOU-ASSI SG，HABIB A，et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk forearly death[J].Hepatology，2004，40:802-810.
[23] ROSSLE M，OCHS A，GULBERG V，et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites[J]. N Engl J Med，2000，342:1701-1707.
[24] LEBREC D，GIUILY N，HADENGUE A，et al. Transjugular intrahepatic portosystemic shunts:comparison with paracentesis in patients with cirrhosis and refractory ascites:a randomized trial[J]. J Hepatol，1996，25:135-144.
[25] SANYAL AJ，GENNING C，REDDY RK，et al. The North American study for the treatment Of refractory ascites[J]. Gastroenterology，2003，124:634-641.
[26] SALERNO F，MERLI M，RIGGIO O，et al. Randomized controlled study of TIPS vs. paracentesis plus albumin in cirrhosis with severe ascites[J]. Hepatology，2004，40:629-635.
[27] SAAB S，NIETO JM，KY D，et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites[J]. Cochrane Database Syst Rev，2004，3:CD004889.
[28] DELTENRE P，MATHURIN P，DHARANCY S，et al. Transjugular intrahepatic portosystemic shunt in refractory ascites:ameta-analysis[J]. Liver Int，2005，25:349-356.
[29] ALBILLOS A，BANARES R，GONZALEZ M，et al. A meta analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractoryascites[J]. J Hepatol，2005，43:990-996.
[30] D'AMICO G，LUCA A，MORABITO A，et al. Uncover transjugular intrahepatic portosystemic shunt for refractory ascites:a meta-analysis[J]. Gastroenterology，2005，129:1282-1293.
[31] SAAB S，NIETO JM，LEWIS SK，et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites[J]. Cochrane Database Syst Rev，2006，4:CD004889.
[32] SALERNO F，CAMMA C，ENEA M，et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data[J]. Gastroenterology，2007，133:825-834.
[33] POZZI M，CARUGO S，BOARI G，et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites[J]. Hepatology，1997，26:1131-1137.
[34] AZOULAY D，CASTAING D，DENNISON A，et al. Transjugular intrahepatic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study[J]. Hepatology，1994，19:129-132.
[35] RABIE R，CAZZANIGA M，SALERNO F，et al. The effect of cirrhotic cardiomyopathy on the post-TIPS outcome of patients treated for complications of portal hypertension [Abstract][J]. Hepatology，2006，44:444A.
[36] MICH LP，GULBERG V，BILZER M，et al. Transjugular intrahepatic portosystemic shunt for cirrhosis and ascites: effects in patients with organic or functional renal failure[J]. Scand J Gastroenterol，2000，35:654-657.
[37] BUREAU C，GARCIA-PAGAN JC，OTAL P，et al. Improved clinical outcome using polytetrafluoroethylenecoated stents for TIPS: results of a randomized study[J]. Gastroenterology，2004，126:469-475.
[38] ANGERMAYR B，CEJNA M，KOENIG F，et al. Survival in patients undergoing transjugular intrahepatic portosystemic shunt:ePTFE-covered stentgrafts versus bare stents[J]. Hepatology，2003，38:1043-1050.
[39] MALINCHOC M，KAMATH PS，GORDON FD，et al. A Modelto predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology，2000，31:864-871.
[40] BOYER TD，HASKAL ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension[J]. Hepatology，2005，41:1-15.
[41] ROSEMURGY AS，ZERVOS EE，CLARK WC，et al. TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites:a prospective and randomized trial[J]. Ann Surg，2004，239:883-891.
[42] PARK JS，WON JY，PARK SI，et al. Percutaneous peritoneovenous shunt creation for the treatment of benign and malignant refractory ascites[J]. J Vasc Interv Radiol，2001，12:1445-1448.
[43] ROSENBLUM DI，GEISENGER MA，NEWMANJS，et al. Use of subcutaneous venous access ports to treat refractory ascites[J]. J Vasc Interv Radiol，2001，12:1343-1346.
[44] ROZENBLIT GN，DELGUERCIO LRM，RUNDBACK JH，et al. Peritoneal-urinary drainage for treatment of refractory ascites:a pilot study[J]. J Vasc Interv Radiol，1998，9:998-1005.
[45] TROTTER J，PIERAMICI E，EVERSON GT. Chronic albumin infusions to achieve dieresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt（TIPS）[J]. Dig Dis Sci，2005，50:1356-1360.
[46] ROMANELLI RG，LAVILLA G，BARLETTA G，et al. Long-term albumin infusionim proves survival in patients with cirrhosis and ascites:an unblinded randomized trial[J]. World J Gastroenterol，2006，12:1403-1407.
[47] LENAERTS A，CODDEN T，MEUNIER JC，et al. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system[J]. Hepatology，2006，44:844-849.
[48] LENAERTS A，CODDEN T，HENRYJ-P，et al. Comparative pilot study of repeated large volume paracentesis vs the combination of clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites[J]. Gastroenterol Clin Biol， 2005，29:1137-1142.
[49] KAAMBOKIS G，FOTOPOULOS A，ECONOMOU M，et al. Octreotide in the treatment of refractory ascites of cirrhosis[J].Scand J Gastroenterol，2006，41:118-121.

肝硬化顽固性腹水的治疗新进展^*

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[6]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[7]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[8]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[9]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[10]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[11]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[12]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[13]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[14]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[15]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.